1. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2). Issue 2 (6th February 2019) Authors: Geven, Christopher; Blet, Alice; Kox, Matthijs; Hartmann, Oliver; Scigalla, Paul; Zimmermann, Jens; Marx, Gernot; Laterre, Pierre-François; Mebazaa, Alexandre; Pickkers, Peter Journal: BMJ open Issue: Volume 9:Issue 2(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2). Issue 2 (6th February 2019) Authors: Geven, Christopher; Blet, Alice; Kox, Matthijs; Hartmann, Oliver; Scigalla, Paul; Zimmermann, Jens; Marx, Gernot; Laterre, Pierre-François; Mebazaa, Alexandre; Pickkers, Peter Journal: BMJ open Issue: Volume 9:Issue 2(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Adrenomedullin in heart failure: pathophysiology and therapeutic application. (28th December 2018) Authors: Voors, Adriaan A.; Kremer, Daan; Geven, Christopher; ter Maaten, Jozine M.; Struck, Joachim; Bergmann, Andreas; Pickkers, Peter; Metra, Marco; Mebazaa, Alexandre; Düngen, Hans‐Dirk; Butler, Javed Journal: European journal of heart failure Issue: Volume 21:Number 2(2019) Page Start: 163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Bioactive Adrenomedullin, Organ Support Therapies, and Survival in the Critically Ill: Results from the French and European Outcome Registry in ICU Study. Issue 1 (January 2020) Authors: Lemasle, Léa; Blet, Alice; Geven, Christopher; Cherifa, Ményssa; Deniau, Benjamin; Hollinger, Alexa; Fournier, Marie-Céline; Monnet, Xavier; Rennuit, Isabelle; Darmon, Michael; Laterre, Pierre-François; Struck, Joachim; Hartmann, Oliver; Bergmann, Andreas; Mebazaa, Alexandre; Gayat, Etienne Journal: Critical care medicine Issue: Volume 48:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis. Issue 6 (December 2018) Authors: Geven, Christopher; Peters, Esther; Schroedter, Mathias; Struck, Joachim; Bergmann, Andreas; McCook, Oscar; Radermacher, Peter; Kox, Matthijs; Pickkers, Peter Journal: Shock Issue: Volume 50:Issue 6(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first‐in‐human study and during experimental human endotoxaemia in healthy subjects. (3rd July 2018) Authors: Geven, Christopher; van Lier, Dirk; Blet, Alice; Peelen, Roel; ten Elzen, Bas; Mebazaa, Alexandre; Kox, Matthijs; Pickkers, Peter Journal: British journal of clinical pharmacology Issue: Volume 84:Number 9(2018) Page Start: 2129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in Sepsis. Issue 2 (August 2018) Authors: Geven, Christopher; Bergmann, Andreas; Kox, Matthijs; Pickkers, Peter Journal: Shock Issue: Volume 50:Issue 2(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗